Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
IPO Year:
Exchange: NASDAQ
Website: capricor.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2024 | $35.00 | Overweight | Piper Sandler |
| 5/17/2024 | $14.00 | Outperform | Oppenheimer |
| 1/5/2024 | $8.00 | Overweight | Cantor Fitzgerald |
| 10/26/2022 | $15.00 | Buy | Ladenburg Thalmann |
| 1/31/2022 | $14.00 → $18.00 | Buy | HC Wainwright & Co. |
| 10/11/2021 | $9.00 → $14.00 | Buy | HC Wainwright & Co. |
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
SCHEDULE 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
DEF 14A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
10-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
S-8 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
SCHEDULE 13G - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing deep experience in neuromuscular and rare diseasesThe National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in the
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 13, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 73741Participants can use g
-Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date- SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. During
Philip Gotwals, Ph.D. and Steve Crouse bring strategic and operational experience in business development and global tools and technology OmniAb, Inc. (NASDAQ:OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb's partnership base. These Board changes are effective immediately and increase the number of Directors to seven. "We're delighted to welcome Phil and Steve to our Board of Directors. Their extensive
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company will present at the 2025 Piper Sandler Virtual Cardio Day taking place on April 2, 2025. Capricor will take part in a fireside chat to discuss the company's latest advancements on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general regulatory, scientific and corporate updates. Capricor Therapeutics Fireside Chat Date: Wednesday, April 2, 2025Time: 12:00–12:30 p.m. ETParticipants: Linda
Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathyBLA granted priority review with a Prescription Drug User Fee Act (PDUFA) target action date set for August 31, 2025 Reported positive data from HOPE-2 open label extension (OLE) trial at 2025 MDA Conference showing preservation of skeletal muscle function over 3 years resulting in 52% slowing of disease Received $10 million milestone payment from Nippon Shinyaku; cash balance of approximately $152 million at year-end 2024 expected to support current planned operations into 2027Capricor to host conference call and
--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference-- SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive long-term data from its ongoing HOPE-2 open label extension ("OLE") clinical trial, demonstrating the potential of the Company's lead asset, deramiocel, to slow disease progression and preserve upper limb function in patients with Duchenne muscular dystrophy ("DMD"). The
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 19, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on March 19. Title:Capricor Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, March 19, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-18
PARAMUS, N.J., March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that acceptance has been received by Capricor Therapeutics, Inc. (Headquarters: California, USA, CEO: Linda Marbán, (Headquarters: California, USA, CEO: Linda Marbán, NASDAQ:CAPR) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) filing for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy. The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of August 31, 202
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
SC 13G - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)
Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing deep experience in neuromuscular and rare diseasesThe National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in the
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 13, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 73741Participants can use g
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 19, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on March 19. Title:Capricor Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, March 19, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-18
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on November 13. Title:Capricor Therapeutics Third Quarter 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, November 13, 2024Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 680
-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA- -Initial Label Would Include All Patients with Cardiomyopathy Associated with Duchenne Muscular Dystrophy- -Rolling Submission Planned to Commence in October 2024- -Internal GMP Manufacturing Established to Support BLA and Commercialization- -Investor Webcast Today at 8:30 a.m. ET- SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today, following recent meetings with the U.S. Food and Drug Administration (FDA), its intent to file
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will host an investor webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET to provide an update on its Duchenne muscular dystrophy (DMD) program. The update will consist of the latest regulatory updates following the Company's recent meetings with the U.S. Food and Drug Administration (FDA). Webcast Details Capricor will host a conference call and webcast at 8:30 a.m. ET on Tuesday, September 24, 2024. To participate in the conference call, please dial 1-800-71
-Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On Track to Report Top-Line Data from Cohort A in Q4 2024- -Reported Positive 3-Year Skeletal and Cardiac Data from HOPE-2 Open-Label Extension Trial- -Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the second quarter ended June 3
-Company to Host Conference Call, August 7, 2024 at 4:30 p.m. ET- SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the second quarter ended June 30, 2024, after the market close on Wednesday, August 7, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on August 7. Title:Capricor Therapeutics Second Quarter 2024 Financial Results and Recent Corporate Update Conference Call and Webcast Date:Wednesday, August 7, 2024 Time:4:30 p.m. ET Conference Call Details:Toll-Free:
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical Comparability, A Major Milestone on Path to CMC Clearance for BLA– –Received First Milestone Payment of $10 Million under U.S. Distribution and Commercialization Agreement with Nippon Shinyaku in Q1– –Recent FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission at Upcoming Type-B Clinical FDA Meeting in May 2024– –Plan to Report 3-Year Data from HOPE-2 Open-Label Extension (OLE) Trial in Q2 2024– –Conference Call
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2024, after the market close on Monday, May 13, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Monday, May 13, 2024Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-888-886-7786International: 1-416-764-8658Conference ID: 01529679Participants can use
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment of Philip J. Gotwals, Ph.D., to its Board of Directors, effective immediately. Dr. Gotwals, most recently the Global Head, Vice President of Business Development and Licensing at Novartis Institutes for Biomedical Research, brings his strategic vision for research, innovation for drug development and valuable industry experience to the Company. "It is a pleasure to welcome Philip to our Board of Directo
-John Hopkins School of Medicine Clinical Director Joins Capricor's Board of Directors with over 30 Years of Internal Medicine and Infectious Disease Experience- SAN DIEGO, July 13, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment of Paul Auwaerter, M.D. to its Board of Directors, effective immediately. Dr. Auwaerter brings over three decades of experience in internal medicine and infectious disease to Capricor. "I am extremely pleased to welcome Dr. Auwaerter to our Bo
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards Lifesciences, Gilead and Genentech, Mr. Avat Brings Over 25 Years of Business and Commercial Strategy Experience to Capricor SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that it has appointed Xavier Avat as Chief Business Officer. In this role, Mr. Avat will oversee Capricor's strateg
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today the expansion of its Senior Leadership team with the appointment of Daniel Paulson, M.D. as Vice President of Clinical Development. "On behalf of the entire Capricor team, we welcome Dr. Paulson to the Company," said Linda Marbán, Ph.D., Capricor's Chief Executive Officer. "Daniel is a distinguished leader in the industry and his extensive experience in global pharmaceutical drug development will be instrumental as we conti
LOS ANGELES, July 27, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics ("Capricor" or "the Company") (NASDAQ:CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, today announced the appointment of Karimah Es Sabar to its Board of Directors, effective immediately. Ms. Es Sabar is a highly regarded and established leader in life sciences industry and brings over 35 years of global business management experience to Capricor. "I am delighted to welcome Ms. Es Sabar to our Board of Directors," said Linda Marbán, Ph.D., Capricor's CEO. "Her extensive work experience and background across
Piper Sandler initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $35.00
Oppenheimer initiated coverage of Capricor Therapeutics with a rating of Outperform and set a new price target of $14.00
Cantor Fitzgerald initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $8.00
Ladenburg Thalmann initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $15.00
HC Wainwright & Co. reiterated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $18.00 from $14.00 previously
HC Wainwright & Co. reiterated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $14.00 from $9.00 previously